Bispecific Antibodies - Research Paper Example

In recent years, antibody therapy has become a new treatment modality for tumor patients, although the majority of responses are only partial and long-antihanging. Based on evidence that effecter- cell-mediated mechanisms significantly contribute to antibody efficacy in vivo, several approaches are currently perused to improve the interaction between Fc receptor-expressing effecter cells and tumor target antigens. For these purposes, the invention of monoclonal antibodies in vivo started. In the initiation, phase the results were not satisfactorily and this antipodicities trials in vivo showed only 20% clearance of the tumor cells but after letting it go through different formatting processes it went up to achieve 80% clearance. Bispecific antibodies have got 2 hinging sites which are specific for getting attached to immune recruiting cells and also to target antigens which are mostly transformed cells. “Bispecific antibodies (Sab) can, by combining two binding specificities, improve the selectivity and efficacy of antibody-based treatment of human disease. Recent studies underline the importance of both the ‘anti-trigger’ and ‘anti-target’ modalities of Sab for therapeutic efficacy”. (Spriel, A.B., Ojik, H.H.V, & Winkel, J.G.J. 2000). There has always been an issue of side effects when it comes to cancer therapy and a lot of patients would not even go for therapies due the bad side effects. In the past few decade’s things have started improving the standard mode of ontological therapies which were chemotherapy and radiation it is now switching more towards treatment of cancer with more of antibiotic and immunoglobulin. This has brought a lot of hope for future success in getting a strong hold of cancer with fewer emergences of side effects. Bispecific antibodies do not occur in nature and they need to be synthesized in vivo, through either recombinant DNA, or cell fusion technique.  “Bispecific antibodies have been manufactured by fusing the DNA encoding a single chain antibody (ScFv) after the C terminus (CH3-ScFv) or after the hinge (Hinge-ScFv) with an antibody of a different specificity.